文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

体能状态评分:患者与他们的肿瘤医生意见一致吗?

Performance status score: do patients and their oncologists agree?

作者信息

Blagden S P, Charman S C, Sharples L D, Magee L R A, Gilligan D

机构信息

Department of Oncology, Box 193, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK.

出版信息

Br J Cancer. 2003 Sep 15;89(6):1022-7. doi: 10.1038/sj.bjc.6601231.


DOI:10.1038/sj.bjc.6601231
PMID:12966419
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2376959/
Abstract

Oncologists traditionally assess their patients' ECOG performance status (PS), and few studies have evaluated the accuracy of these assessments. In this study, 101 patients attending a rapid access clinic at Papworth Hospital with a diagnosis of lung cancer were asked to assess their own ECOG PS score on a scale between 0 and 4. Patients' scores were compared to the PS assessment of them made by their oncologists. Of 98 patients with primary non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), weighted kappa statistics showed PS score agreement between patient and oncologist of 0.45. Both patient- and oncologist-assessed scores reflected survival duration (in NSCLC and SCLC) as well as disease stage (in NSCLC), with oncologist-assessed scores being only marginally more predictive of survival. There was no sex difference in patient assessment of PS scores, but oncologists scored female patients more pessimistically than males. This study showed that, with few exceptions, patients and oncologists assessed PS scores similarly. Although oncologists should continue to score PS objectively, it may benefit their clinical practice to involve their patients in these assessments.

摘要

肿瘤学家传统上会评估患者的东部肿瘤协作组(ECOG)体能状态(PS),但很少有研究评估这些评估的准确性。在本研究中,邀请了101名在帕普沃思医院快速就诊诊所被诊断为肺癌的患者,让他们在0至4的量表上评估自己的ECOG PS评分。将患者的评分与肿瘤学家对他们的PS评估进行比较。在98例原发性非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC)患者中,加权kappa统计显示患者与肿瘤学家之间的PS评分一致性为0.45。患者和肿瘤学家评估的评分均反映了生存时间(在NSCLC和SCLC中)以及疾病分期(在NSCLC中),肿瘤学家评估的评分对生存的预测性仅略高一些。患者对PS评分的评估不存在性别差异,但肿瘤学家对女性患者的评分比对男性患者更悲观。这项研究表明,除了少数例外情况,患者和肿瘤学家对PS评分的评估相似。虽然肿瘤学家应继续客观地对PS进行评分,但让患者参与这些评估可能会有益于他们的临床实践。

相似文献

[1]
Performance status score: do patients and their oncologists agree?

Br J Cancer. 2003-9-15

[2]
Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer.

Br J Cancer. 2001-11-30

[3]
Should patient-rated performance status affect treatment decisions in advanced lung cancer?

J Thorac Oncol. 2008-10

[4]
Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.

JAMA Netw Open. 2021-2-1

[5]
Differences in Performance Status Assessment Among Palliative Care Specialists, Nurses, and Medical Oncologists.

J Pain Symptom Manage. 2015-6

[6]
Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.

Eur J Cancer. 1996-6

[7]
Performance status agreement assessed by the patient and clinician in a rapid access lung cancer service: Can either predict completion of treatment?

Eur J Cancer Care (Engl). 2019-2-13

[8]
Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer.

Oncologist. 2019-6-21

[9]
Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.

Curr Probl Cancer. 2020-6

[10]
The Functionality Assessment Flowchart (FAF): a new simple and reliable method to measure performance status with a high percentage of agreement between observers.

BMC Cancer. 2015-7-5

引用本文的文献

[1]
Are oncologists and their patients on the same page? - Exploring clinician-patient agreement in performance status reporting.

Support Care Cancer. 2025-6-21

[2]
The prognostic role of Geriatric 8 in patients with cancer: a meta-analysis and systematic review.

Oncologist. 2025-6-4

[3]
Impact of Collaborative Empowerment Education on Psychological Distress, Quality of Life, and Nutritional Status in Esophageal Cancer Patients Undergoing Concurrent Chemoradiotherapy.

J Cancer Educ. 2025-3-31

[4]
Smartphone-based measures as real-world indicators of functional status in advanced cancer patients.

medRxiv. 2025-2-7

[5]
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Blood Adv. 2025-5-13

[6]
A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers.

BMC Cancer. 2025-1-21

[7]
Incidence and determinants of mortality among patients with colorectal cancer in oncology centers of Amhara region, Ethiopia, 2024: multicenter retrospective follow up study.

BMC Cancer. 2025-1-18

[8]
Patient-reported performance status and postoperative complications in elective colorectal cancer surgery.

Int J Colorectal Dis. 2024-11-21

[9]
Acute kidney injury in hematological patients treated with CAR-T cells: risk factors, clinical presentation and impact on outcomes.

Sci Rep. 2024-11-6

[10]
Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis.

Ann Hematol. 2024-10

本文引用的文献

[1]
Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group.

Int J Radiat Oncol Biol Phys. 2002-10-1

[2]
Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?

J Clin Oncol. 2002-9-15

[3]
Prognostic factors in non-small cell lung cancer: a decade of progress.

Chest. 2002-9

[4]
Depression and functional status as predictors of death among cancer patients.

Cancer. 2002-5-15

[5]
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .

Cancer. 2001-11-15

[6]
Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer.

Br J Cancer. 2001-11-30

[7]
Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer.

Cancer Chemother Pharmacol. 2000

[8]
Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data.

J Clin Oncol. 2000-2

[9]
Observer error in grading performance status in cancer patients.

Support Care Cancer. 1999-9

[10]
Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.

Eur J Cancer. 1996-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索